Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
In what patients is it inappropriate to offer DCISionRT testing?
Related Questions
Does radiation therapy (ex. to the breast) in patients with CDK4 mutations increase the risk of developing melanoma?
How do you optimally set a patient up for breast radiation therapy if you don't have access to a breast board or wing board?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
How do you manage symptomatic fat necrosis following adjuvant breast radiotherapy?
What are your top takeaways in Breast Cancer from ASCO 2025?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Is it appropriate to use bolus with hypofractionated PMRT?
Does micropapillary subtype for a G1-2 DCIS affect your radiation treatment recommendations?
Would a longstanding diagnosis of multiple sclerosis impact your radiation recommendations for a patient with breast cancer?
